These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33973894)

  • 1. Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States.
    Faiz AS; Guo S; Kaveney A; Philipp CS
    Blood Coagul Fibrinolysis; 2021 Sep; 32(6):373-381. PubMed ID: 33973894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Xu X; Chlebowski RT; Shi J; Barac A; Haque R
    Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis.
    Yu Q; Xu Y; Yu E; Zheng Z
    J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
    Kovac M; Kovac Z; Tomasevic Z; Vucicevic S; Djordjevic V; Pruner I; Radojkovic D
    Eur J Intern Med; 2015 Jan; 26(1):63-7. PubMed ID: 25592075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
    Santorelli ML; Hirshfield KM; Steinberg MB; Rhoads GG; Lin Y; Demissie K
    Ann Epidemiol; 2016 Jun; 26(6):436-40. PubMed ID: 27157863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen and risk of idiopathic venous thromboembolism.
    Meier CR; Jick H
    Br J Clin Pharmacol; 1998 Jun; 45(6):608-12. PubMed ID: 9663819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
    Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J
    Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
    Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C
    Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
    Mayer EL; Burstein HJ
    Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant endocrine therapy in breast cancer. Management of early-risk relapse].
    Chahine G; Howayek M; Atallah D
    J Med Liban; 2009; 57(2):124-9. PubMed ID: 19623889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
    Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
    Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.
    Deitcher SR; Gomes MP
    Cancer; 2004 Aug; 101(3):439-49. PubMed ID: 15274057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort.
    Blondon M; Bodmer A; Thouvenin L; Lecompte T; Righini M; Fontana P; Casini A
    Blood Adv; 2022 May; 6(9):2884-2892. PubMed ID: 35086148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended Endocrine Therapy: Is 5 Years Enough?
    Bhave MA; Henry NL
    Curr Oncol Rep; 2017 Mar; 19(3):16. PubMed ID: 28251491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
    Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG
    Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical Estrogen Prescription Fill Rates for Women With a History of Breast Cancer Who Are Taking Hormone Therapy.
    Huntley JH; Richter LA; Blackford AL; Aliu O; Pollack CE
    Obstet Gynecol; 2018 Nov; 132(5):1137-1142. PubMed ID: 30303924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.